Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

Core Viewpoint - Immunocore Holdings plc, a biotechnology company focused on immunomodulating medicines, will report its financial results for Q4 and the year ended December 31, 2024, on February 26, 2025 [1]. Company Overview - Immunocore is pioneering a novel class of TCR bispecific immunotherapies known as ImmTAX, aimed at treating various diseases including cancer, autoimmune diseases, and infectious diseases [4]. - The company has developed a deep pipeline across multiple therapeutic areas, with its leading oncology TCR therapeutic, KIMMTRAK, already approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [4]. Upcoming Events - Following the financial results announcement, the company will host a live teleconference and webcast on February 26, 2025, at 8:00 a.m. EST to discuss the results and provide a business update [2]. - The webcast will be accessible through the company's website, and a replay will be available for a limited time after the event [3]. Contact Information - For inquiries, Immunocore's Head of Communications is Sébastien Desprez, reachable at +44 (0) 7458030732 or via email at sebastien.desprez@immunocore.com [7]. - Investor relations can be contacted through Clayton Robertson or Morgan Warenius at +1 (215) 384-4781 or ir@immunocore.com [7].